KALA vs. NRBO, BIVI, COCP, SYBX, TCRT, INDP, LUMO, SLGL, ORGS, and AYTU
Should you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include NeuroBo Pharmaceuticals (NRBO), BioVie (BIVI), Cocrystal Pharma (COCP), Synlogic (SYBX), Alaunos Therapeutics (TCRT), Indaptus Therapeutics (INDP), Lumos Pharma (LUMO), Sol-Gel Technologies (SLGL), Orgenesis (ORGS), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical preparations" industry.
KALA BIO (NASDAQ:KALA) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.
NeuroBo Pharmaceuticals' return on equity of -90.22% beat KALA BIO's return on equity.
KALA BIO has a beta of -1.75, meaning that its stock price is 275% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500.
KALA BIO presently has a consensus target price of $16.50, suggesting a potential upside of 151.91%. NeuroBo Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 114.59%. Given KALA BIO's higher probable upside, research analysts clearly believe KALA BIO is more favorable than NeuroBo Pharmaceuticals.
NeuroBo Pharmaceuticals has lower revenue, but higher earnings than KALA BIO.
In the previous week, KALA BIO had 3 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 4 mentions for KALA BIO and 1 mentions for NeuroBo Pharmaceuticals. NeuroBo Pharmaceuticals' average media sentiment score of 0.80 beat KALA BIO's score of -0.77 indicating that NeuroBo Pharmaceuticals is being referred to more favorably in the news media.
24.6% of KALA BIO shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 13.4% of KALA BIO shares are held by insiders. Comparatively, 0.5% of NeuroBo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
KALA BIO received 271 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 66.67% of users gave KALA BIO an outperform vote.
Summary
KALA BIO beats NeuroBo Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get KALA BIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KALA BIO Competitors List
Related Companies and Tools
